CurrentCapital BluecrossPolicy MP 4.047

Laser treatment for vulvovaginal atrophy and vaginal rejuvenation

This policy governs coverage determinations for fractional and fractional CO2 laser procedures for vulvovaginal atrophy, vaginal rejuvenation, and vaginal tightening for members of applicable Capital BlueCross products.

Policy Summary

PayerCapital Bluecross

PolicyLaser treatment for vulvovaginal atrophy and vaginal rejuvenation

Policy CodePolicy MP 4.047

Change TypeNo material change

Effective DateSep 1, 2025

Next Review DateN/A

Key ActionThese procedures are listed as non-covered; verify member benefit terms and prior authorization requirements for specific products before scheduling.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

1Procedure code listed as non-covered

3Typical treatment sessions described

2020-2025Policy history entries span

ACOG citedRelevant professional guidance referenced

Coverage Determination

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage determination

Policy stance

Policy conclusion: Treatment of vulvovaginal atrophy with fractional or fractional CO2 lasers is investigational for all indications; vaginal rejuvenation and vaginal tightening procedures using these lasers are cosmetic and non-covered.

Insufficient evidence to determine effects on net health outcomes; safety and long-term outcomes not established.

Vaginal rejuvenation and vaginal tightening procedures that use fractional or fractional CO2 lasers to improve appearance or enhance sexual performance are considered cosmetic and therefore non-covered under this policy. (See coding section for applicable non-covered procedure code.)

The evidence is insufficient to support the safety and effectiveness of fractional laser treatments for vulvovaginal atrophy; accordingly, such treatments are considered investigational and non-covered. Available literature does not establish clinical utility, long-term outcomes, or complication rates, and randomized controlled trials with long-term follow-up are needed to evaluate efficacy and safety.

Provider Actions & Claims

Denial Risk

Non-covered / Investigational Procedures

Treatment of vulvovaginal atrophy with fractional laser or fractional carbon dioxide (CO2) laser devices is considered investigational and non-covered. Vaginal rejuvenation and vaginal tightening procedures using these lasers are considered cosmetic and non-covered. Final claims payment is subject to the member's benefit terms, eligibility on the date of service, and applicable contract limitations and exclusions.

Investigational/non-covered: fractional laser and fractional CO2 laser treatments for vulvovaginal atrophy and vaginal rejuvenation (Procedure code: 58999 may be used; identification of a code does not denote coverage).
Cosmetic/non-covered: vaginal rejuvenation and vaginal tightening to improve appearance or sexual performance.

Billing Rule

Coverage Determination and Claims Processing

Claims payment for services described in this policy is subject to a determination that the services are medically necessary and appropriate, and to the member's benefit program and eligibility on the date of service. Providers should verify member benefits and prior authorization requirements (when applicable) before rendering services. These medical policies do not guarantee coverage or payment.

Payment is contingent on member eligibility and benefit terms.
Final claim processing is governed by the member's contract, including limitations and exclusions.
If questions about coverage exist, contact Capital BlueCross Provider Services or Member Services.

Note

Preferred/Established Therapy

Preferred and established therapy for vulvovaginal atrophy typically involves hormone therapy (e.g., topical or systemic estrogen) and other standard treatments. Providers should consider these established options when managing atrophy due to menopause, cancer treatment, medication effects, or prolonged breastfeeding.

Standard treatment options include hormone therapy as first-line management for vulvovaginal atrophy.
Non-laser alternatives (topical moisturizers, lubricants, and systemic therapies) may be appropriate per clinical judgment and member benefits.

Clinical Background

Vulvovaginal atrophy, also referred to as the genitourinary syndrome of menopause, results from estrogen loss and commonly causes thinning of the vaginal epithelium, decreased lubrication, inflammation, and symptoms such as vaginal dryness, burning, itching, dyspareunia (painful intercourse), and urinary complaints. Proposed laser therapies aim to thermally remodel vaginal collagen, but current evidence is inadequate to confirm long-term benefit or safety.

Key Definitions

Vaginal Relaxation Syndrome (VRS) — definition/clinical note

DefinitionLaxity of the vaginal wall resulting in loss of friction and sexual satisfaction for the patient and her partner.

Common causesFrequently associated with vaginal childbirth and natural aging.

Clinical impactCan result in decreased sexual satisfaction due to reduced vaginal wall friction.

Typical non-surgical interventions describedFractional and fractional CO2 laser treatments have been proposed to thermally remodel collagen in the vaginal wall to thicken and tighten tissue; usually delivered as three sessions spaced about 4–6 weeks apart.

Potential complications of laser treatmentInfection, loss or alteration of sensation, pain (including pain during intercourse), adhesions, and scarring.

Vulvovaginal atrophy — definition/clinical note

DefinitionAtrophy of vulvovaginal tissues due to estrogen loss (also called vaginal atrophy, urogenital atrophy, or atrophic vaginitis).

Typical symptomsThinning, dryness, inflammation, dyspareunia, burning, itching, urinary frequency, and recurrent bladder infections.

Common causesMenopause-related estrogen loss; may also result from cancer treatment/radiation, certain medications, or prolonged breastfeeding.

Established treatmentsStandard treatment options typically involve hormone therapy for atrophy due to menopause.

Context regarding lasersFractional and fractional CO2 lasers have been proposed as non-surgical treatments to remodel collagen and improve atrophy, but safety and long-term effectiveness are not established (policy considers such laser treatments investigational/non-covered).